Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Kyverna Therapeutics, Inc. (KYTX)
NASDAQ:KYTX
Kyverna Therapeutics, Inc. (KYTX) Stock Price & Analysis
567 Followers
KYTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$6.75 - $35.06
Previous Close$7.01
Volume584.06K
Average Volume (3M)597.56K
Market Cap
$302.02M
Enterprise Value$253.56M
Total Cash (Recent Filing)$57.54M
Total Debt (Recent Filing)$9.08M
Price to Earnings (P/E)―
Beta-0.26
Next Earnings
May 14, 2024EPS Estimate
-$0.84Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding43,115,244
10 Day Avg. Volume1,326,474
30 Day Avg. Volume597,564
Standard Deviation0.16
R-Squared0.80
Alpha-0.25
Financial Highlights & Ratios
Price to Book (P/B)-2.54
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$30.67Price Target Upside337.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Kyverna Therapeutics, Inc. News
Bulls Say, Bears Say
Bulls Say
Clinical DataThe breadth of data generated with KYV-101 continues to impress, with experience being accumulated across multiple trial sites and investigators.
EfficacyA broader efficacy update across all 30 KYV-101-treated patients showed that all patients achieved rapid and deep B cell depletion, with the majority (28/30) achieving significant disease impact.
Safety ProfileKYV-101's safety profile to date continues to look clean across the 50 total patients dosed, with only manageable side effects.
Bears Say
Clinical DataRecent KYV-101 data in LN left much to be desired in the next update.
Efficacy ConcernsAnalysts remain skeptical of the ability for a low-dose, one-time DNA-modified CAR-T therapy to produce deep and durable responses in the autoimmune setting.
Market CompetitionKYV-101, along with other DNA-modified CAR-T therapeutics, may face tough competition from RNA-modified CAR-Ts that can be dosed multiple times and at higher aggregate dose levels per cycle.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
KYTX FAQ
What was Kyverna Therapeutics, Inc.’s price range in the past 12 months?
Kyverna Therapeutics, Inc. lowest stock price was $6.75 and its highest was $35.06 in the past 12 months.
What is Kyverna Therapeutics, Inc.’s market cap?
Currently, no data Available
When is Kyverna Therapeutics, Inc.’s upcoming earnings report date?
Kyverna Therapeutics, Inc.’s upcoming earnings report date is May 14, 2024 which is 54 days ago.
How were Kyverna Therapeutics, Inc.’s earnings last quarter?
Kyverna Therapeutics, Inc. released its earnings results on Mar 26, 2024. The company reported -$17.21 earnings per share for the quarter, missing the consensus estimate of -$0.703 by -$16.507.
Is Kyverna Therapeutics, Inc. overvalued?
According to Wall Street analysts Kyverna Therapeutics, Inc.’s price is currently Undervalued.
Does Kyverna Therapeutics, Inc. pay dividends?
Kyverna Therapeutics, Inc. does not currently pay dividends.
What is Kyverna Therapeutics, Inc.’s EPS estimate?
Kyverna Therapeutics, Inc.’s EPS estimate is -$0.84.
How many shares outstanding does Kyverna Therapeutics, Inc. have?
Kyverna Therapeutics, Inc. has 43,115,246 shares outstanding.
What happened to Kyverna Therapeutics, Inc.’s price movement after its last earnings report?
Kyverna Therapeutics, Inc. reported an EPS of -$17.21 in its last earnings report, missing expectations of -$0.703. Following the earnings report the stock price went up 2.387%.
Which hedge fund is a major shareholder of Kyverna Therapeutics, Inc.?
Among the largest hedge funds holding Kyverna Therapeutics, Inc.’s share is Deerfield Management Company, LP. It holds Kyverna Therapeutics, Inc.’s shares valued at 36M.
---
Kyverna Therapeutics, Inc. Stock Smart Score
Company Description
Kyverna Therapeutics, Inc.
Kyverna Therapeutics is a cell therapy company engineering a new class of therapies for autoimmune and inflammatory diseases. The Kyverna therapeutic platform combines advanced T-cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the origin of autoimmune and inflammatory diseases. Kyverna¿s pipeline includes next-generation chimeric antigen receptor T-cell (CAR T) therapies in both autologous and allogeneic formats with properties well suited for use in B cell-driven autoimmune diseases.
---
KYTX Stock 12 Month Forecast
Average Price Target
$30.67
▲(337.83% Upside)
Technical Analysis
Best Analysts Covering KYTX
1 Year
1 Year Success Rate
0/3 ratings generated profit
1 Year Average Return
-46.90%
reiterated a buy rating 18 days ago
Copying Thomas Smith's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -46.90% per trade.
---